A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Oral Pentamidine

Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days

OTHER

Placebo

Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days

Trial Locations (3)

T2N4Z6

Dr. Kelly Burak, Calgary

M5G 2N2

Dr Morris Sherman, Toronto

H2X 3J4

Dr Marc Bilodeau, Montreal

Sponsors
All Listed Sponsors
lead

Oncozyme Pharma Inc.

INDUSTRY